HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Or Not To Be? ODI, NDI Or IND?

This article was originally published in The Rose Sheet

Executive Summary

Cannabidiol is found in the hemp plant and other sources and is not an intoxicant, but a "human neurotransmitter and a normal part of the cannabidiol neurotransmitter system in the human body," says "Vitamin Lawyer" Ralph Fucetola.

You may also be interested in...



Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting

FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.

FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test

FDA's warnings that supplements containing cannabis-derived ingredients are adulterated comes 10 months year after it stated the policy and a year after submitting other warnings that stopped short of saying the ingredients are noncompliant.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel